ezetimibe + efavirenz

Ezetimibe + efavirenz is a combination therapy used in HIV-infected patients with hyperlipidemia. Ezetimibe is a cholesterol absorption inhibitor that reduces the absorption of cholesterol from foods and the production of cholesterol in the body. Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used as part of highly active antiretroviral therapy (HAART) for the treatment of HIV type 1. Clinical studies have shown that ezetimibe may be a safe and efficient therapeutic option in patients with HIV infection on efavirenz-containing regimens, as ezetimibe had no effect on the disposition of efavirenz, and efavirenz did not significantly impact the lipid-lowering effects of ezetimibe.